Publications in collaboration with researchers from Hackensack University Medical Center (6)

2021

  1. Idecabtagene vicleucel in relapsed and refractory multiple myeloma

    New England Journal of Medicine, Vol. 384, Núm. 8, pp. 705-716

  2. KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma

    Blood Cancer Journal, Vol. 11, Núm. 6

2020

  1. A dose-finding Phase 2 study of single agent isatuximab (anti-CD38 mAb) in relapsed/refractory multiple myeloma

    Leukemia, Vol. 34, Núm. 12, pp. 3298-3309

2016

  1. International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment

    Journal of Clinical Oncology, Vol. 34, Núm. 13, pp. 1544-1557

2013

  1. Phase Ib study of panobinostat and bortezomib in relapsed or relapsed and refractory multiple myeloma

    Journal of Clinical Oncology

2009

  1. Panobinostat and Bortezomib Phase I Trial in Multiple Myeloma

    CLINICAL LYMPHOMA & MYELOMA